Navigation Links
GEN Reports on the Trend Toward Predictive Toxicogenomics
Date:11/19/2008

NEW ROCHELLE, N.Y., Nov. 19 /PRNewswire/ -- Biotech scientists increasingly are applying genomics technologies to toxicology research to better understand the effects of novel drug candidates on a variety of organ systems, reports Genetic Engineering & Biotechnology News (GEN). They are especially interested in figuring out a new compound's mechanism of action and eventually developing a predictive toxicology technique, according to the November 15 issue of GEN. (http://www.genengnews.com/articles/chitem.aspx?aid=2675)

"Toxicogenomics, which is essentially gene-expression profiling, is the next step up from basic toxicology studies," says John Sterling, Editor-in-Chief of GEN. "It is a more complex approach, and it will take some time before it becomes a regular tool in the technology armentarium of drug discovery and pharmaceutical scientists."

So far most companies are focusing on toxicogenomics primarily as a method to explore mechanisms of action rather than to predict toxicity. Roche, for example, uses toxicogenomics to generate hypotheses when trying to unravel the cellular machinery underlying toxicity responses, which then are tested more thoroughly using other assays. Novartis is employing known toxic compounds to develop the techniques to understand the mechanistic actions of toxicity. Such screening led to the recent validation of biomarkers for kidney toxicity.

Groups such as The C-Path Predictive Safety Testing Consortium are examining published toxicogenomics multiple gene biomarkers or signatures and trying to validate those signatures across laboratories.

Also covered in the GEN article is work being carried out by Amgen, Entelos, Lilly Research Laboratories, Hamner Institutes for Health Sciences, and the Health and Environmental Sciences Institute.

For a copy of the November 15 issue of GEN, please call (914) 740-2122, or email: ebicovny@liebertpub.com

Genetic Engineering & Biotechnology News (www.genengnews.com), which is published 21 times a year by Mary Ann Liebert, Inc. (www.liebertpub.com), is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Clinical Research and Diagnostics.

Contact: John Sterling, Editor in Chief, Genetic Engineering & Biotechnology News, (914) 740-2196, jsterling@genengnews.com


'/>"/>
SOURCE Genetic Engineering & Biotechnology News
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
4. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
8. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
9. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
10. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
11. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
(Date:5/26/2016)... May 26, 2016 Since its ... into an essential life science tool for conducting genetic ... BCC Research reveals in its new report that the ... phase, one powered by a range of new applications ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the Federal ... an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at ... Committee (FOMC) dot charts are of interest to the press for their noise potential,” ...
(Date:5/26/2016)... Missouri (PRWEB) , ... May 26, 2016 , ... ... quality and clinical outcomes, hosted members and suppliers for its inaugural Member Conference ... focus on their mission of elevating the operational health of America’s healthcare providers. ...
(Date:5/26/2016)... ... , ... The Woodlands at John Knox Village , Florida’s first Life ... living and healing, celebrated its grand opening, today. The Woodlands at John Knox Village ... Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village as ...
(Date:5/26/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... global clinical supply services, today announced two key appointments and the opening of ... strategic growth plans in the Asia Pacific region. , Howard Kim has joined ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial ... is sharing tips to make sure your family and vehicle are ready to ... Council, there may be 439 deaths and an additional 50,500 serious injuries from motor ...
Breaking Medicine News(10 mins):